Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NDAC Chair

This article was originally published in The Tan Sheet

Executive Summary

An "Appointed Chair" for the Nonprescription Drugs Advisory Committee will run meetings until a final selection is made for a permanent chair, according to FDA. Previous NDAC Chairman Alastair Wood, MD, concluded his term May 31. Wood will begin his role as a managing director at the New York-based private equity firm Symphony Capital in September (1"The Tan Sheet" May 8, 2006, p. 3) A permanent Chair normally is selected from the committee...

You may also be interested in...

NDAC’s Wood Departs FDA Committee; Joins Private Investment Firm

Nonprescription Drugs Advisory Committee Chairman Alastair Wood, MD, will depart NDAC in May and take a position at New York-based private equity firm Symphony Capital, the company announced May 1

More Top-Level Pharma Changes In India, Cipla Gets CSO

Top-level personnel movement continues at pharma firms in India, with Cipla now appointing an ex-Amneal executive as its Chief Scientific Officer, while Abbott has effected a rejig at the helm.

India Acts To Limit Supply Disruption From Coronavirus

Indian pharmaceutical companies will soon be asked to seek a no objection certificate for the export of 12 APIs and their formulations, as the country deals with Chinese raw material supply disruptions on the back of the coronavirus crisis. However, the move is not expected to impact the export quantum for now.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts